Literature DB >> 16575001

White race as a risk factor for hypothyroidism after treatment for pediatric Hodgkin's lymphoma.

Monika L Metzger1, Melissa M Hudson, Grant W Somes, Ron I Shorr, Chin-Shang Li, Matthew J Krasin, John Shelso, Ching-Hon Pui, Scott C Howard.   

Abstract

PURPOSE: Hypothyroidism frequently occurs after treatment for pediatric Hodgkin's lymphoma, but race has not been investigated as a risk factor for this delayed toxicity. The aim of this study was to determine whether race is an independent risk factor for hypothyroidism in survivors of pediatric Hodgkin's lymphoma. PATIENTS AND METHODS: To identify differences between black and white patients in the development of hypothyroidism after treatment for Hodgkin's lymphoma, we conducted a retrospective study of consecutively treated pediatric patients with newly diagnosed Hodgkin's lymphoma treated at St Jude Children's Research Hospital (Memphis, TN) from January 1980 through December 2002. Clinical or biochemical hypothyroidism was defined by an above normal thyroxine-stimulating hormone concentration or by the need for thyroid hormone replacement therapy.
RESULTS: The 461 patients (388 white patients, 73 black patients) where followed for a median of 11.3 years (range, 1.8 to 24.9 years). Hypothyroidism developed in 196 (43%) of 461 patients after a median of 2.9 years (range, 0.7 to 11.3 years) after diagnosis of Hodgkin's lymphoma. Hypothyroidism developed in 47% of white patients but in only 21% of black patients (hazard ratio = 2.7; 95% CI, 1.6 to 4.6). After adjusting for other risk factors for hypothyroidism (thyroid radiation dose, sex, and nodular sclerosis histology), the risk of hypothyroidism in white patients was 2.5 times (95% CI, 1.5 to 4.3 times) the risk in black patients (P < .001).
CONCLUSION: White patients have a higher risk of hypothyroidism after neck irradiation for pediatric Hodgkin's lymphoma than black patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16575001     DOI: 10.1200/JCO.2005.05.0195

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

Review 1.  Late effects of therapy for Hodgkin's lymphoma.

Authors:  Michael Jacob Adams; Louis S Constine; Steven E Lipshultz
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

Review 2.  Screening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer.

Authors:  Emily S Tonorezos; Melissa M Hudson; Angela B Edgar; Leontien C Kremer; Charles A Sklar; W Hamish B Wallace; Kevin C Oeffinger
Journal:  Lancet Diabetes Endocrinol       Date:  2015-04-12       Impact factor: 32.069

3.  Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy.

Authors:  Chelsea C Pinnix; Laura Cella; Therese Y Andraos; Zeina Ayoub; Sarah A Milgrom; Jillian Gunther; Sonali Thosani; Christine Wogan; Manuel Conson; Vittoria D'Avino; Yasuhiro Oki; Michelle Fanale; Hun J Lee; Sattva Neelapu; Luis Fayad; Frederick Hagemeister; M Alma Rodriguez; Loretta J Nastoupil; Yago Nieto; Wei Qiao; Roberto Pacelli; Bouthaina Dabaja
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-03-14       Impact factor: 7.038

4.  Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma.

Authors:  Jeremy M Sharib; Jobin Cyrus; Andrew Horvai; Florette K Gray Hazard; John Neuhaus; Katherine K Matthay; Robert Goldsby; Neyssa Marina; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2011-12-16       Impact factor: 3.167

Review 5.  High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance.

Authors:  Melissa M Hudson; Daniel A Mulrooney; Daniel C Bowers; Charles A Sklar; Daniel M Green; Sarah S Donaldson; Kevin C Oeffinger; Joseph P Neglia; Anna T Meadows; Leslie L Robison
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

6.  An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials.

Authors:  Maurie Markman; Judy Petersen; Robert Montgomery
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-28       Impact factor: 4.553

Review 7.  Hypothyroidism after a cancer diagnosis: etiology, diagnosis, complications, and management.

Authors:  Yvette Carter; Rebecca S Sippel; Herbert Chen
Journal:  Oncologist       Date:  2013-12-05

Review 8.  An Underestimated Toxicity Radiation-Induced Hypothyroidism in Patients Multimodally Treated for Breast Cancer.

Authors:  Camil Ciprian Mireștean; Roxana Irina Iancu; Dragoș Petru Teodor Iancu
Journal:  J Clin Med       Date:  2021-11-24       Impact factor: 4.241

9.  Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: is it better than three dimensional conformal radiotherapy?

Authors:  Vitaliana De Sanctis; Chiara Bolzan; Marco D'Arienzo; Stefano Bracci; Alessandro Fanelli; Maria Christina Cox; Maurizio Valeriani; Mattia F Osti; Giuseppe Minniti; Laura Chiacchiararelli; Riccardo Maurizi Enrici
Journal:  Radiat Oncol       Date:  2012-08-02       Impact factor: 3.481

10.  Thyroid abnormalities in survivors of childhood cancer.

Authors:  Ayla Akca Çağlar; Aynur Oğuz; Faruk Güçlü Pınarlı; Ceyda Karadeniz; Arzu Okur; Aysun Bideci; Ülker Koçak; Hüseyin Bora
Journal:  J Clin Res Pediatr Endocrinol       Date:  2014-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.